Note to editors
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
References
Publications cited during the Talk
- Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry
- Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies
- Evaluation and management of patients with heart disease and cancer: cardio-oncology
- Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer